HARNESSING THE BENEFIT OF
NOVEL CAR-T THERAPY
We are developing innovative immune therapies such as BAFFR CAR-T therapy to improve the lives of patients with cancer and immune disorders.
About PeproMene bio inc.
PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. We are committed to developing novel therapies to treat cancers and immune disorders. Our BAFF-R CAR-T therapy program is based on a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R) discovered by Dr. Larry Kwak’s team at MD Anderson Cancer Center, Houston, Texas, and City of Hope National Medical Center, Duarte, California.
Science
BAFF (B cell activating factor), a soluble cytokine expressed by B cells is known for its proliferation and differentiation. In particular, BAFF-R (B cell activating factor receptor) is an excellent potential target for B-cell cancers not only because of its specificity on the BAFF, but also for its expression level by lymphoproliferative as well as leukemia-proliferative disorders.
Pipeline
Pipeline
- B-cell malignancies
- Autoimmune Disorders
Pipeline
Investors
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma
News link: A lymphoma survivor talks about his treatments with CAR T-cell therapy to fight cancer | Lymphoma Awareness Month - CBS Los Angeles
An article from City of Hope: Relapsed Lymphoma Patient Thrives After CAR T Cell Trial
PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells
PeproMene’s platform and products targeting BAFF-R which is an innovative tumor antigen for treating a broad range of B cell malignancies and autoimmune diseases. BAFF-R targeting immune therapies have great potential to overcome the tumor relapse caused by antigen loss brings hope to those patients with such unmet medical needs. We value investors who share the same passion and welcome you to contact us for further information.
